September 5, 2024

Uncategorized

New Releases from NCBI BookshelfAtogepant (Qulipta): Indication: For the prevention of migraine in adults who have at least 4 migraine days per month: CADTH Reimbursement Recommendation [Internet].​Atogepant (Qulipta): Indication: For the prevention of migraine in adults who have at least 4 migraine days per month: CADTH Reimbursement Recommendation [Internet].

CADTH recommends that atogepant (Qulipta) be reimbursed by public drug plans for the prevention of migraine if certain conditions are

Uncategorized

New Releases from NCBI BookshelfReview of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update: Rapid Review [Internet].​Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update: Rapid Review [Internet].

Multiple sclerosis is a chronic autoimmune disorder that causes damage to central nervous system cells. Relapsing-remitting multiple sclerosis is characterized

Scroll to Top